Compare Inovio Pharmaceuticals Inc (INO) vs PulteGroup, Inc. (PHM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Inovio Pharmaceuticals Inc vs PulteGroup, Inc. — how do they compare? Inovio Pharmaceuticals Inc trades at $1.08 (market cap $89.27M), while PulteGroup, Inc. trades at $122.51 (market cap $23.46B). The key difference: PulteGroup, Inc. is far larger — about 262.8× Inovio Pharmaceuticals Inc's market cap, and PulteGroup, Inc. pays a 0.84% dividend while Inovio Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| INO | PHM | |
|---|---|---|
Market Cap | $89.27M | $23.46B |
Sector | Health | Consumer Cyclical |
52-Week High | $2.87 | $142.56 |
52-Week Low | $1.05 | $108.65 |
Enterprise Value | $60.28M | $23.42B |
Dividend Yield | — | 0.84% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
INO trades at $1.10, down 1.79% recently, with a bearish technical signal from moving averages. The company shows minimal revenue of $65,340 in 2025 and a net loss of $84.95 million, resulting in negative profitability margins. Recent news highlights an ongoing FDA review for INO-3107 with a PDUFA date of October 30, 2026, while shareholder litigation investigations emerge. Cash flow remains negative, though operating expenses have declined.
The investment case hinges on the binary FDA decision for INO-3107, offering potential upside if approved, but carries high risk due to persistent losses, negative cash flow, and legal scrutiny. Analyst consensus is moderately bullish with 53% buy ratings, but fundamental weaknesses and technical bearishness suggest cautious positioning is warranted.
PulteGroup (PHM) trades at $124.26, down 1.44% over the past day, with technical indicators showing a bearish trend. The stock exhibits strong profitability with a net income margin of 12.14% and ROE of 16.18%, though recent quarters saw mixed earnings results. Valuation ratios remain attractive with a P/E of 11.91 and P/S of 1.44. Recent news highlights institutional activity and anticipation for Q2 2026 earnings, with the company expanding communities amid housing market challenges.
The outlook for PHM is cautiously optimistic, supported by solid fundamentals and a consensus price target of $146.50 implying 18% upside. Risks include margin pressure from high mortgage rates and competitive discounts. Analyst sentiment is balanced with 45% buy ratings, but investors should monitor earnings execution and housing demand trends for sustained growth.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Inovio Pharmaceuticals Inc
Inovio Pharmaceuticals Inc is a United States based biotechnology company that develops active DNA-based immunotherapies and vaccines to treat and prevent cancers and infectious diseases. The company is engaged in gene therapy, where its immunotherapy platform consists of DNA-based immunotherapy and electroporation delivery technologies.
Read more on INO →About PulteGroup, Inc.
PulteGroup Inc is one of the largest homebuilders in the United States, operating in 40 markets across 23 states. The company mainly builds single-family detached homes (85% of unit sales) and offers products to entry-level, move-up, and active-adult buyers. PulteGroup offers homebuyers mortgage financing and title agency services through its financial services segment. The company is headquartered in Atlanta.
Read more on PHM →
